ZFP36L2 and Arthritis: have reported that in vivo administration of PP2A agonists such as COG1410 (an apolipoprotein E peptide mimetic) or AAL(s) (a lipid derivative of the immunosuppressant FTY720 (Fingolimod)) activates ZFP36 through the dephosphorylation and ameliorates experimental murine arthritis models (45). Although the precise roles of ZFP36L2 in T cell function and inflammatory diseases remain to be elucidated, we have reported that ZFP36L2 reduces HELIOS expression in iTregs and suppresses iTreg function (Figure 2) (8).